Skip to main content
. 2022 Sep 16;82(22):4288–4298. doi: 10.1158/0008-5472.CAN-21-2483

Figure 5.

Figure 5. Sensitivity of Probody TCB to protease cleavage correlates with efficacy and intratumoral T-cell presence in PBMC-engrafted NSG mice. A, NSG mice harboring HT29-Luc2 tumors and engrafted with human PBMCs were treated on days 1, 8, and 15 with vehicle (PBS) or 0.3 mg/kg CI020, CI011, CI040, or CI048 (n = 8 per group). Tumor volume was measured twice weekly. B, NSG mice harboring HT29-Luc2 tumors and engrafted with human PBMCs were treated with vehicle or 1 mg/kg of CI020, CI011, CI040, or CI048. Tumors were harvested 7 days after dosing, and immunohistochemistry for CD3 was performed. Brown stain indicates CD3+ cells.

Sensitivity of Probody TCB to protease cleavage correlates with efficacy and intratumoral T-cell presence in PBMC-engrafted NSG mice. A, NSG mice harboring HT29-Luc2 tumors and engrafted with human PBMCs were treated on days 1, 8, and 15 with vehicle (PBS) or 0.3 mg/kg CI020, CI011, CI040, or CI048 (n = 8 per group). Tumor volume was measured twice weekly. B, NSG mice harboring HT29-Luc2 tumors and engrafted with human PBMCs were treated with vehicle or 1 mg/kg of CI020, CI011, CI040, or CI048. Tumors were harvested 7 days after dosing, and immunohistochemistry for CD3 was performed. Brown stain indicates CD3+ cells.